FDA Adverse Event Injury Summary report: N

ASR UNI FEMORAL IMPL SIZE 46

MDR report key: 3192763 · Received June 27, 2013

Report

Report Number
1818910-2013-19972
Event Type
Injury
Date Received
June 27, 2013
Date of Event
June 20, 2013
Report Date
October 4, 2013
Manufacturer
DEPUY INTL., LTD. - 8010379
Product Code
KWA
PMA / PMN Number
PK040627
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. REF. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

DEPUY STILL CONSIDERS THIS INVESTIGATION CLOSED.

Additional Manufacturer Narrative · 1

DEPUY STILL CONSIDERS THIS INVESTIGATION CLOSED.

Description of Event or Problem · 1

**UPDATE**(B)(4) 2013 - LITIGATION PAPERS RECEIVED. LITIGATION ALLEGES DISCOMFORT AND ELEVATED METAL ION LEVELS. DOI PROVIDED. THERE IS NO NEW ADDITIONAL INFORMATION THAT WOULD AFFECT THE INVESTIGATION.

Description of Event or Problem · 1

PATIENT UNDERWENT LEFT HIP REVISION PROCEDURE DUE TO PAIN AND OSTEOLYSIS.

Description of Event or Problem · 1

**UPDATE** - MEDICAL RECORDS RECEIVED (B)(4) 2013. REVISION OPERATIVE REPORT INDICATES THE FOLLOWING: LOOSE CUP; METALLOSIS; PAIN; MINIMAL ELEVATED COBALT AND CHROMIUM LEVELS; 5 ML OF THICK MUCINOUS WATERY FLUID WITH A SLIGHTLY GRAYISH APPEARANCE; SCAR TISSUE; GRAYISH AND METAL STAINED SYNOVIUM.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
292120 ASR UNI FEMORAL IMPL SIZE 46 FEMORAL HEAD KWA DEPUY INTL., LTD. - 8010379 2050175

Patients

Seq Age Sex Outcome Treatment
1 78 YR Required Intervention